Cargando…
Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study
Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may have the potential of additive therapeutic b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431088/ https://www.ncbi.nlm.nih.gov/pubmed/22966460 http://dx.doi.org/10.1155/2012/935921 |
_version_ | 1782242027550801920 |
---|---|
author | Jacques, F. Gaboury, I. Christie, S. Grand'Maison, F. |
author_facet | Jacques, F. Gaboury, I. Christie, S. Grand'Maison, F. |
author_sort | Jacques, F. |
collection | PubMed |
description | Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may have the potential of additive therapeutic benefit through the complementary mechanisms of action of these two therapeutics. In this randomized, open-label, multicenter, two-arm pilot study, the authors examined the safety and tolerability of the combination of interferon beta-1b and tacrolimus in relapsing remitting (RRMS) and secondary progressive (SPMS) multiple sclerosis patients who have failed one or more immunomodulatory therapies. Patients (n = 25) received a combination of interferon beta-1b subcutaneously every other day and oral tacrolimus (low blood level tacrolimus, 1–5 ng/mL, or high blood level tacrolimus, 5–10 ng/mL) for a period of 38 weeks. The combination therapy of interferon beta-1b and tacrolimus over the 10-month period of the study was shown to be safe and relatively well tolerated. There were no unexpected adverse events occurring as the result of the combination therapy. Further study of this combination therapy in patients with multiple sclerosis unresponsive to conventional therapy is warranted. |
format | Online Article Text |
id | pubmed-3431088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34310882012-09-10 Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study Jacques, F. Gaboury, I. Christie, S. Grand'Maison, F. Mult Scler Int Clinical Study Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may have the potential of additive therapeutic benefit through the complementary mechanisms of action of these two therapeutics. In this randomized, open-label, multicenter, two-arm pilot study, the authors examined the safety and tolerability of the combination of interferon beta-1b and tacrolimus in relapsing remitting (RRMS) and secondary progressive (SPMS) multiple sclerosis patients who have failed one or more immunomodulatory therapies. Patients (n = 25) received a combination of interferon beta-1b subcutaneously every other day and oral tacrolimus (low blood level tacrolimus, 1–5 ng/mL, or high blood level tacrolimus, 5–10 ng/mL) for a period of 38 weeks. The combination therapy of interferon beta-1b and tacrolimus over the 10-month period of the study was shown to be safe and relatively well tolerated. There were no unexpected adverse events occurring as the result of the combination therapy. Further study of this combination therapy in patients with multiple sclerosis unresponsive to conventional therapy is warranted. Hindawi Publishing Corporation 2012 2012-08-15 /pmc/articles/PMC3431088/ /pubmed/22966460 http://dx.doi.org/10.1155/2012/935921 Text en Copyright © 2012 F. Jacques et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Jacques, F. Gaboury, I. Christie, S. Grand'Maison, F. Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study |
title | Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study |
title_full | Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study |
title_fullStr | Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study |
title_full_unstemmed | Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study |
title_short | Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study |
title_sort | combination therapy of interferon beta-1b and tacrolimus: a pilot safety study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431088/ https://www.ncbi.nlm.nih.gov/pubmed/22966460 http://dx.doi.org/10.1155/2012/935921 |
work_keys_str_mv | AT jacquesf combinationtherapyofinterferonbeta1bandtacrolimusapilotsafetystudy AT gabouryi combinationtherapyofinterferonbeta1bandtacrolimusapilotsafetystudy AT christies combinationtherapyofinterferonbeta1bandtacrolimusapilotsafetystudy AT grandmaisonf combinationtherapyofinterferonbeta1bandtacrolimusapilotsafetystudy |